Comparative Medicine Services Core

Since its inception, the CHOP Research Institute has held a “bench to bedside” philosophy that emphasizes bringing basic research ideas to the clinic so that they may improve the lives of our patients and their families.  Completion of nonclinical investigations and submission of an Investigational New Drug (IND) application or a Premarket Approval (PMA) application to the FDA for the approval of first-in-human clinical trials are essential steps toward enacting this philosophy.  The mission of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics Comparative Medicine Services Core (CMSC) is to partner with and guide investigators through these processes.
The Comparative Medicine Services Core is currently developing the capacity for GLP-compliance.  All nonclinical programs require in-depth planning and discussions.  Therefore, we encourage you to contact us as soon as you believe you have a drug or device that will eventually require human clinical trials prior to use in patients.  The Comparative Medicine Services Core is composed of highly-trained professionals capable of completing and overseeing a variety of animal studies.  We adhere to the highest standards of animal welfare, procedure reproducibility and validation, and customer service.